相关实验视频

Updated: May 15, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

集成基于药的虚拟查,分子对接,ADMET分析和MD模拟以准EGFR:使用商业数据库进行全面的药物发现研究

Abdullah R Alanzi¹, Ashaimaa Y Moussa², Mohammed S Alsalhi³

¹Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

|December 9, 2024

概括

这项研究通过计算查表皮肤生长因子受体 (EGFR) 抑制剂来确定潜在的抗癌药物. 分子动力学模拟证实了三个有前途的化合物的稳定性,以便进一步进行实验研究.

科学领域:

在瘤学瘤学.
计算化学计算化学
药理学药理学是指药理学的学科.

背景情况:

皮表皮生长因子受体 (EGFR) 是癌症治疗的关键标,因为它经常失调.
向EGFR是开发新型抗癌药物的验证战略.

研究的目的:

确定新的小分子作为表皮生长因子受体 (EGFR) 的潜在抑制剂.
为了利用针对EGFR的药物发现的综合计算方法.

主要方法:

基于EGFR联合晶体合体 (PDB ID: 7AEI) 的药解体建模.
在九个数据库中进行基于干的虚拟选,然后使用Glide工具对EGFR受体进行对接.
预测ADMET属性和分子动力学 (MD) 模拟 (200 ns) 用于分析顶级化合物的稳定性.

主要成果:

从虚拟选中选择了1271个成功结果.
前十大化合物显示的结合亲和度在 -7.691 到 -7.338 kcal/mol.之间.
三种化合物 (MCULE-6473175764,CSC048452634,CSC070083626) 呈现出有利的ADMET特性,并通过MD模拟证实与EGFR的稳定相互作用.

结论:

已识别的化合物显示出作为抑制EGFR生物活性的化合物的潜力.
需要进一步的实验验证,以确认这些潜在EGFR抑制剂的治疗疗效.

更多相关视频

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...